VG Life Sciences, Inc. Reports on Scientific Advancements:
Completion of Third Cohort of Phase I Clinical Trial; Grant from
the American Heart Association; UniQuest Reports on LipidMax
SANTA BARBARA, Calif.,
July 25, 2013 /PRNewswire/--- VG Life
Sciences, (OTC Pink: VGLS) a biotechnology company, announces today
several advancements as it relates to its scientific
advancements
Cancer Study Update
Favorable safety data has allowed this study to advance to the
fourth and final cohort of phase I. The phase I study has
been aimed at examining the safety and efficacy of one of Dr.
Karen Newell's Metabolic Disruption
Technology compounds, hydroxychloroquine (HCQ), in combination with
an existing cancer drug, sorafenib (marketed as Nexavar™). This
combination treatment has been administered to patients with many
different carcinomas. This study is being conducted at the Cancer
Therapy & Research Center in San
Antonio and the Scott and White Hospital system located in
Temple, Texas. "Now that the
hurdle of safety is nearly surmounted, we are eager to move into a
systematic analysis of the reactions in each group's carcinomas,"
says Dr. Karen Newell.
American Heart Association Grant
Dr. Karen Roger-Newell and Dr.
Brett Mitchell, both professors at
Texas A&M, have jointly received a
$140,000 grant from the American
Heart Association to study the application of the Targeted Peptide
Technology (TPT) as it relates to preeclampsia (PE) over a two-year
period. "Preliminary data in mice indicate that the treatment not
only prevented the development of preeclampsia but also abolished
preeclampsia after it had been established as blood pressure and
urinary protein levels were normalized within 2-3 days of treatment
and there were beneficial effects on fetal development," says Dr.
Brett Mitchell. "By targeting
specific detrimental immune cells and leaving beneficial protective
immune cells alone, the Company's treatment may represent a novel
therapy for women with preeclampsia." Specifically, their team will
research the role that CLIP+ gamma delta T-cells have in the
role in the pathology of PE, and determine the role that
these gamma delta T-cells play in blood pressure regulation.
Preeclampsia is characterized by the de novo onset of
hypertension and proteinuria; it is one of the most common medical
disorders during pregnancy, affecting ~8% of all pregnancies
world-wide.
Report from UniQuest on VG Energy's LipidMax Technology in
Algae
UniQuest Pty. Ltd, the commercialization arm of the University of Queensland, Australia, with a team
led by Dr. Ben Hankamer, has
completed the final report on VG Energy's LipidMax compound in
algae biofuel. The researchers were able to offer additional third
party verification that Lipid Max can increase the yield of oil in
algae. Further, the researchers were able to show that LM can
increase yields in strains resistant to nitrogen depletion as well
as in C. protothecoides, a known lipid producing strain.
Importantly, the researchers were able to determine that later
addition of LM in the algae growth cycle was more effective due to
increased algae concentrations.
Ben Hankamer is the director of the
Solar Biofuels Consortium, which brings together seven
international teams and approximately 100 researchers
(www.solarbiofuels.org) working on biofuels and production
optimization. The consortium fosters close partnerships with
industries that have synergy to establish effective value chains
including the biotechnology, engineering, oil, airline and
manufacturing industries.
The Hankamer report may be viewed here.
About VG Life Sciences Inc.
Santa Barbara, California-based VG
Life Sciences Inc., formerly known as Viral Genetics, is a
biotechnology company focused on discovering and developing drug
therapies for cancer, infectious disease, and inflammatory,
autoimmune disorders. VGLS controls over 50 US and international
patents and pending patents protecting its exclusive biotech
platform technologies. For more information and upcoming events,
visit www.vglifesciences.com or find VG Life Sciences, Inc. on
Facebook, Twitter, and LinkedIn.
Safe Harbor Statement and Forward-Looking Statements
This news release may contain forward-looking statements that
involve risks and uncertainties associated with financial
projections, milestone timelines, clinical development, regulatory
approvals and other risks described by VG Life Sciences from time
to time in its periodic reports. None of VG Life Sciences' drug
compounds are approved by the US FDA or by any comparable
regulatory agencies elsewhere in the world. Therefore, there can be
no assurance that the forward-looking statements included in this
release will prove to be accurate. In light of the significant
uncertainties inherent in the forward-looking statements included
herein, the forward-looking statements should not be regarded as a
representation by VG Life Sciences or any other person that the
objectives and plans of VG Life Sciences will be achieved.
Contact:
Alexandria Sumner, Corporate
Communications
VG Life Sciences, Inc.
Phone: (805) 679-6763
Email: Alex@vglifesciences.com
SOURCE VG Life Sciences, Inc.